FIT-2 is a multi-country, phase IIb, randomized, non-comparative study, carried out in West
Africa (Côte d'Ivoire, Burkina Faso, Senegal, Togo).
ARV-naïve HIV-2 infected adult patients will be recruited and followed during 96 weeks.
The objective is to evaluate the efficacy and safety of 3 first-line treatments in HIV-2
infected adult patients, in West Africa. A treatment will be considered as effective if more
than 55% of patients in that arm attain "global success" at 96 weeks.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)